Expertise in
5
conditions

Calogero Vetro

Catania, IT 
Expertise in
5
conditions
Catania, IT 

Overview

Calogero Vetro practices practicing medicine in Catania, Italy.

Mr. Vetro is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Hodgkin Lymphoma, Febrile Neutropenia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 76 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Catania, Italy
Other Locations
Bolzano, 39100, Italy
Brescia, Italy
Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (allo-SCT)
Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (allo-SCT)
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Combination product
Study Phase: Phase 2
Prospective Survey on Severe Infections During a Multicenter Study of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia.
Prospective Survey on Severe Infections During a Multicenter Study of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia.
Enrollment Status: Terminated
Publish Date: October 12, 2022
Intervention Type: Other
View 1 Less Clinical Trial

76 Total Publications

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.
Journal: British journal of haematology
Published: February 25, 2026

Frequently Asked Questions about Calogero Vetro

Is Calogero Vetro a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Calogero Vetro is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Calogero Vetro participate in research or clinical trials?

Yes. Calogero Vetro has published 76 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Calogero Vetro's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vetro's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile